Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women | New England Journal of Medicine (nejm.org)
Population:
Study Participants: Adolescent girls and young women in South Africa and Uganda.
Sample Size: 5338 participants who were initially HIV-negative.
Intervention:
Primary Intervention: Subcutaneous lenacapavir administered every 26 weeks.